接种Sputnik V疫苗后阿根廷卫生保健工作者血清流行率

D. Santonato, María A. Malvicini, A. Novau, S. Torres, A. Siaba Serrate, María V. Romano, P. Brenzoni, L. Fabbro, L. Paulosky, W. Cornistein
{"title":"接种Sputnik V疫苗后阿根廷卫生保健工作者血清流行率","authors":"D. Santonato, María A. Malvicini, A. Novau, S. Torres, A. Siaba Serrate, María V. Romano, P. Brenzoni, L. Fabbro, L. Paulosky, W. Cornistein","doi":"10.3396/ijic.v18.21791","DOIUrl":null,"url":null,"abstract":"Background: Healthcare workers (HCW) were deeply affected by coronavirus disease 2019 (COVID-19). Therefore, vaccination of this population is crucial. However, data on Sputnik V vaccine are sparse. Objective: The aim of this study was to evaluate serological responses in HCWs following two doses of Sputnik V vaccine. Methods: A cross-sectional study was conducted at a tertiary-care private teaching hospital between April and May 2021. HCWs without a history of COVID-19 3 or more weeks after the second dose of Sputnik V had a fresh serum sample extracted and processed using Abbott® SARS-CoV-2 IgG II Quant. Values equal to or over 50 arbitrary units (AU)/mL were considered positive. Primary outcome was the proportion of participants who developed antibodies 21 or more days after the second dose of Sputnik V. Secondary outcomes were concentration of anti-spike IgG antibodies and comparison of such concentrations between samples taken 3–5 weeks and more than 5 weeks after the second dose. Results: The entire population developed anti-spike IgG antibodies. The median antibody concentration was 1234.8 AU/mL. When analysing days to extraction from second vaccine dose, there was no statistical difference between 21 and 35 days versus more than 35 days. Conclusion: Vaccination with Sputnik V in HCW at our institution demonstrated an efficacy of 100% in achieving quantifiable anti-spike IgG antibodies 21 or more days after the second dose.","PeriodicalId":13991,"journal":{"name":"International Journal of Infection Control","volume":"28 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Seroprevalence in Argentinian healthcare workers after vaccination with Sputnik V\",\"authors\":\"D. Santonato, María A. Malvicini, A. Novau, S. Torres, A. Siaba Serrate, María V. Romano, P. Brenzoni, L. Fabbro, L. Paulosky, W. Cornistein\",\"doi\":\"10.3396/ijic.v18.21791\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Healthcare workers (HCW) were deeply affected by coronavirus disease 2019 (COVID-19). Therefore, vaccination of this population is crucial. However, data on Sputnik V vaccine are sparse. Objective: The aim of this study was to evaluate serological responses in HCWs following two doses of Sputnik V vaccine. Methods: A cross-sectional study was conducted at a tertiary-care private teaching hospital between April and May 2021. HCWs without a history of COVID-19 3 or more weeks after the second dose of Sputnik V had a fresh serum sample extracted and processed using Abbott® SARS-CoV-2 IgG II Quant. Values equal to or over 50 arbitrary units (AU)/mL were considered positive. Primary outcome was the proportion of participants who developed antibodies 21 or more days after the second dose of Sputnik V. Secondary outcomes were concentration of anti-spike IgG antibodies and comparison of such concentrations between samples taken 3–5 weeks and more than 5 weeks after the second dose. Results: The entire population developed anti-spike IgG antibodies. The median antibody concentration was 1234.8 AU/mL. When analysing days to extraction from second vaccine dose, there was no statistical difference between 21 and 35 days versus more than 35 days. Conclusion: Vaccination with Sputnik V in HCW at our institution demonstrated an efficacy of 100% in achieving quantifiable anti-spike IgG antibodies 21 or more days after the second dose.\",\"PeriodicalId\":13991,\"journal\":{\"name\":\"International Journal of Infection Control\",\"volume\":\"28 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Infection Control\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3396/ijic.v18.21791\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infection Control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3396/ijic.v18.21791","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:2019冠状病毒病(COVID-19)对医护人员的影响很大。因此,为这一人群接种疫苗至关重要。然而,关于Sputnik V疫苗的数据很少。目的:本研究的目的是评估两剂Sputnik V疫苗后HCWs的血清学反应。方法:于2021年4月至5月在一家三级私立教学医院进行横断面研究。没有COVID-19病史的医护人员在第二次Sputnik V剂量后3周或更长时间内提取新鲜血清样本,并使用雅培®SARS-CoV-2 IgG II定量仪进行处理,值等于或超过50任意单位(AU)/mL视为阳性。主要结果是在第二次Sputnik v注射后21天或更长时间内产生抗体的参与者比例,次要结果是抗刺突IgG抗体的浓度,以及在第二次注射后3-5周和5周以上的样本之间这种浓度的比较。结果:所有人群均产生抗刺突IgG抗体。抗体中位浓度为1234.8 AU/mL。当分析从第二次疫苗剂量提取的天数时,21天和35天与超过35天之间没有统计学差异。结论:在我们机构的HCW接种Sputnik V疫苗,在第二次接种后21天或更长时间内获得可量化的抗刺突IgG抗体的有效性为100%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Seroprevalence in Argentinian healthcare workers after vaccination with Sputnik V
Background: Healthcare workers (HCW) were deeply affected by coronavirus disease 2019 (COVID-19). Therefore, vaccination of this population is crucial. However, data on Sputnik V vaccine are sparse. Objective: The aim of this study was to evaluate serological responses in HCWs following two doses of Sputnik V vaccine. Methods: A cross-sectional study was conducted at a tertiary-care private teaching hospital between April and May 2021. HCWs without a history of COVID-19 3 or more weeks after the second dose of Sputnik V had a fresh serum sample extracted and processed using Abbott® SARS-CoV-2 IgG II Quant. Values equal to or over 50 arbitrary units (AU)/mL were considered positive. Primary outcome was the proportion of participants who developed antibodies 21 or more days after the second dose of Sputnik V. Secondary outcomes were concentration of anti-spike IgG antibodies and comparison of such concentrations between samples taken 3–5 weeks and more than 5 weeks after the second dose. Results: The entire population developed anti-spike IgG antibodies. The median antibody concentration was 1234.8 AU/mL. When analysing days to extraction from second vaccine dose, there was no statistical difference between 21 and 35 days versus more than 35 days. Conclusion: Vaccination with Sputnik V in HCW at our institution demonstrated an efficacy of 100% in achieving quantifiable anti-spike IgG antibodies 21 or more days after the second dose.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信